Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Trellus Health's Enterprise Value is £-3.07 Mil.
Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.60 Mil. Therefore, Trellus Health's EV-to-EBIT ratio for today is 0.55.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Trellus Health's Enterprise Value is £-3.07 Mil.
Trellus Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.15 Mil. Therefore, Trellus Health's EV-to-EBITDA ratio for today is 0.60.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Trellus Health's Enterprise Value is £-3.07 Mil.
Trellus Health's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was £0.04 Mil. Therefore, Trellus Health's EV-to-Revenue ratio for today is -71.35.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Trellus Health's Enterprise Value is £-3.07 Mil.
Trellus Health's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-6.13 Mil. Therefore, Trellus Health's EV-to-FCF ratio for today is 0.50.
Trellus Health Enterprise Value Historical Data
The historical data trend for Trellus Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Trellus Health's Enterprise Value
For the Health Information Services subindustry, Trellus Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trellus Health's Enterprise Value Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trellus Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Trellus Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Trellus Health's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trellus Health (LSE:TRLS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Trellus Health's current Enterprise Value is £-3.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.60 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Trellus Health's current Enterprise Value is £-3.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.15 Mil.
Trellus Health's current Enterprise Value is £-3.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was £0.04 Mil.
Trellus Health's current Enterprise Value is £-3.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-6.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trellus Health Enterprise Value Related Terms
Thank you for viewing the detailed overview of Trellus Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:TRLS has been successfully added to your